<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>YES.V</title>
  <style>
    /* Default styles provided by pandoc.
    ** See https://pandoc.org/MANUAL.html#variables-for-html for config info.
    */
    html {
      color: #1a1a1a;
      background-color: #fdfdfd;
    }
    body {
      margin: 0 auto;
      max-width: 36em;
      padding-left: 50px;
      padding-right: 50px;
      padding-top: 50px;
      padding-bottom: 50px;
      hyphens: auto;
      overflow-wrap: break-word;
      text-rendering: optimizeLegibility;
      font-kerning: normal;
    }
    @media (max-width: 600px) {
      body {
        font-size: 0.9em;
        padding: 12px;
      }
      h1 {
        font-size: 1.8em;
      }
    }
    @media print {
      html {
        background-color: white;
      }
      body {
        background-color: transparent;
        color: black;
        font-size: 12pt;
      }
      p, h2, h3 {
        orphans: 3;
        widows: 3;
      }
      h2, h3, h4 {
        page-break-after: avoid;
      }
    }
    p {
      margin: 1em 0;
    }
    a {
      color: #1a1a1a;
    }
    a:visited {
      color: #1a1a1a;
    }
    img {
      max-width: 100%;
    }
    svg {
      height: auto;
      max-width: 100%;
    }
    h1, h2, h3, h4, h5, h6 {
      margin-top: 1.4em;
    }
    h5, h6 {
      font-size: 1em;
      font-style: italic;
    }
    h6 {
      font-weight: normal;
    }
    ol, ul {
      padding-left: 1.7em;
      margin-top: 1em;
    }
    li > ol, li > ul {
      margin-top: 0;
    }
    blockquote {
      margin: 1em 0 1em 1.7em;
      padding-left: 1em;
      border-left: 2px solid #e6e6e6;
      color: #606060;
    }
    code {
      font-family: Menlo, Monaco, Consolas, 'Lucida Console', monospace;
      font-size: 85%;
      margin: 0;
      hyphens: manual;
    }
    pre {
      margin: 1em 0;
      overflow: auto;
    }
    pre code {
      padding: 0;
      overflow: visible;
      overflow-wrap: normal;
    }
    .sourceCode {
     background-color: transparent;
     overflow: visible;
    }
    hr {
      border: none;
      border-top: 1px solid #1a1a1a;
      height: 1px;
      margin: 1em 0;
    }
    table {
      margin: 1em 0;
      border-collapse: collapse;
      width: 100%;
      overflow-x: auto;
      display: block;
      font-variant-numeric: lining-nums tabular-nums;
    }
    table caption {
      margin-bottom: 0.75em;
    }
    tbody {
      margin-top: 0.5em;
      border-top: 1px solid #1a1a1a;
      border-bottom: 1px solid #1a1a1a;
    }
    th {
      border-top: 1px solid #1a1a1a;
      padding: 0.25em 0.5em 0.25em 0.5em;
    }
    td {
      padding: 0.125em 0.5em 0.25em 0.5em;
    }
    header {
      margin-bottom: 4em;
      text-align: center;
    }
    #TOC li {
      list-style: none;
    }
    #TOC ul {
      padding-left: 1.3em;
    }
    #TOC > ul {
      padding-left: 0;
    }
    #TOC a:not(:hover) {
      text-decoration: none;
    }
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
    .display.math{display: block; text-align: center; margin: 0.5rem auto;}
  </style>
</head>
<body>
<h1 id="char-technologies-ltd.-tsxv-yes">CHAR Technologies Ltd. (TSXV:
YES)</h1>
<h2 id="business-summary">Business summary</h2>
<ul>
<li>Cleantech developer focused on high temperature pyrolysis (HTP)
converting woody biomass and organics into biocarbons (CleanFyre,
SulfaCHAR) and renewable energy (RNG, green hydrogen).</li>
<li>Primary commercial focus on heavy industry decarbonization,
especially steelmaking where CleanFyre biocarbon is a drop-in
metallurgical coal replacement with materially lower GHG emissions.</li>
<li>Build-Own-Operate (BOO) project model with flagship Thorold, ON
facility under construction; additional projects advancing in Lake
Nipigon, ON and Saint‑Félicien, QC.</li>
<li>HTP platform also applied to PFAS destruction in biosolids while
producing syngas and biochar co-products.</li>
</ul>
<h2 id="recent-developments">Recent developments</h2>
<ul>
<li>Thorold financing and JV: $2.0M corporate private placement from BMI
(May 12, 2025) and $8.0M project-level equity by BMI (Jul 10, 2025)
forming a 50/50 JV for Thorold Phase 1 biocarbon; plan to secure
non‑recourse debt for Phase 2 RNG (target Q4 2025) and RNG commissioning
(target Q3 2026).</li>
<li>Operational progress: 500-tonne pelletized biocarbon production run;
breakthrough in water‑resistant pellets to meet industrial specs and
logistics needs; advancing offtake with major industrials.</li>
<li>PFAS project: Commercial-scale HTP deployment with Synagro at
Baltimore’s Back River facility; performance evaluation underway May–Dec
2025.</li>
<li>Funding and partnerships: Québec $2.5M grant (Programme Innovation
Bois) for Saint‑Félicien; ongoing Clean Fuels Fund draws; FSIIP loan
partial Year 2 disbursement; partnership with LNFMI for Lake Nipigon
facility.</li>
<li>Strategic realignment: Consulting division divested to Cambium (Oct
30, 2024); presented as discontinued operations; related goodwill
impairment recorded in FY2024.</li>
</ul>
<h2 id="key-issues">Key issues</h2>
<ul>
<li>Profitability and revenue mix: Revenue down as the company
transitions away from consulting toward BOO; continued net losses with
lower grant recognition in Q3 FY2025 versus prior year.</li>
<li>Litigation: Ongoing dispute with Actinon related to a terminated
technology license; contingent liability recorded (~US$675k); legal
costs elevated in Q3 FY2025.</li>
<li>Execution and financing risk: Timely completion and scale-up of
Thorold and replication projects depend on securing project finance,
maintaining offtakes, and meeting technical milestones.</li>
<li>Liquidity management: Reliant on staged government funding, equity,
and planned project debt; managing working capital amid construction and
scale-up.</li>
</ul>
<h2 id="financial-summary-cad">Financial summary (CAD $)</h2>
<table style="width:100%;">
<colgroup>
<col style="width: 12%" />
<col style="width: 6%" />
<col style="width: 10%" />
<col style="width: 10%" />
<col style="width: 10%" />
<col style="width: 10%" />
<col style="width: 10%" />
<col style="width: 10%" />
<col style="width: 10%" />
<col style="width: 10%" />
</colgroup>
<thead>
<tr>
<th>Metric</th>
<th>9M FY2025 (YTD)</th>
<th>Q3 FY2025 (Jun 30, 2025)</th>
<th>Q2 FY2025 (Mar 31, 2025)</th>
<th>Q1 FY2025 (Dec 31, 2024)</th>
<th>Q4 FY2024 (Sep 30, 2024)</th>
<th>Q3 FY2024 (Jun 30, 2024)</th>
<th>Q2 FY2024 (Mar 31, 2024)</th>
<th>Q1 FY2024 (Dec 31, 2023)</th>
<th>Q4 FY2023 (Sep 30, 2023)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>1,624,913</td>
<td>437,806</td>
<td>726,968</td>
<td>460,139</td>
<td>1,374,947</td>
<td>1,163,919</td>
<td>881,015</td>
<td>414,686</td>
<td>672,401</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>406,985</td>
<td>51,316</td>
<td>269,997</td>
<td>85,672</td>
<td>530,572</td>
<td>160,081</td>
<td>96,000</td>
<td>184,121</td>
<td>(29,489)</td>
</tr>
<tr>
<td>Operating Income (EBIT)</td>
<td>N/A</td>
<td>(2,168,456)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>(2,141,203)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>EBITDA</td>
<td>N/A</td>
<td>(1,765,286)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>(2,003,171)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>Not reported</td>
<td>Not reported</td>
<td>Not reported</td>
<td>Not reported</td>
<td>Not reported</td>
<td>Not reported</td>
<td>Not reported</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
<tr>
<td>Finance costs (Accretion/Int.)</td>
<td>263,103</td>
<td>82,975</td>
<td>84,983</td>
<td>95,145</td>
<td>N/A</td>
<td>61,822</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Net Income (Loss) – total</td>
<td>(5,505,655)</td>
<td>(2,002,994)</td>
<td>(1,547,308)</td>
<td>(1,955,353)</td>
<td>(2,270,900)</td>
<td>(1,313,591)</td>
<td>(2,377,177)</td>
<td>(2,370,845)</td>
<td>(3,367,414)</td>
</tr>
<tr>
<td>Cash from Operating Activities</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Capital Expenditures (PP&amp;E)</td>
<td>1,350,411</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Free Cash Flow (FCF)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Grant income recognized</td>
<td>457,819</td>
<td>159,575</td>
<td>298,244</td>
<td>—</td>
<td>648,240</td>
<td>821,905</td>
<td>—</td>
<td>23,614</td>
<td>590,301</td>
</tr>
<tr>
<td>Share-based comp expense</td>
<td>509,841</td>
<td>231,403</td>
<td>140,642</td>
<td>137,796</td>
<td>293,386</td>
<td>535,028</td>
<td>422,859</td>
<td>441,437</td>
<td>540,620</td>
</tr>
<tr>
<td>Depreciation</td>
<td>574,? (see note)</td>
<td>256,133</td>
<td>53,986</td>
<td>264,889</td>
<td>246,654</td>
<td>107,268</td>
<td>90,521</td>
<td>78,098</td>
<td>147,638</td>
</tr>
<tr>
<td>Amortization</td>
<td>440,? (see note)</td>
<td>147,037</td>
<td>258,709</td>
<td>34,874</td>
<td>30,765</td>
<td>30,765</td>
<td>174,963</td>
<td>339,063</td>
<td>339,062</td>
</tr>
<tr>
<td>Total Assets (period end)</td>
<td>14,777,335</td>
<td>14,777,335</td>
<td>14,447,120</td>
<td>14,562,831</td>
<td>15,352,471</td>
<td>16,826,809</td>
<td>16,878,443</td>
<td>17,046,837</td>
<td>18,868,473</td>
</tr>
</tbody>
</table>
<p>Notes:</p>
<ul>
<li>Sources: Company MD&amp;A for the quarter ended June 30, 2025
(discussion dated Aug 28, 2025). All figures CAD. Revenue and net income
figures in the “Eight Quarter Summary” include both continuing and
discontinued operations. Where detailed tables were provided (e.g., Q3
FY2025, Q3 FY2024), consolidated values were used by adding discontinued
operations where applicable.</li>
<li>Operating income (EBIT) is defined as Gross Profit minus Operating
Expenses (excludes finance costs and taxes). Exact operating expense
totals were disclosed only for Q3 FY2025 and Q3 FY2024 (continuing +
discontinued), enabling EBIT calculation for those periods:
<ul>
<li>Q3 FY2025 EBIT = 51,316 (Gross Profit) − [2,211,920 (continuing
opex) + 7,853 (disc. opex)] = −2,168,456.</li>
<li>Q3 FY2024 EBIT = 160,081 − [2,110,395 (continuing opex) + 190,890
(disc. opex)] = −2,141,203.</li>
</ul></li>
<li>EBITDA is computed as EBIT + Depreciation + Amortization:
<ul>
<li>Q3 FY2025 EBITDA = −2,168,456 + (256,133 + 147,037) =
−1,765,286.</li>
<li>Q3 FY2024 EBITDA = −2,141,203 + [(105,937 + 1,331) + (30,260 + 505)]
= −2,003,171 (using consolidated D&amp;A; alt. footnote totals: Dep
107,268, Amort 30,765).</li>
</ul></li>
<li>Adjusted EBITDA: not reported by the company.</li>
<li>Finance costs: “Accretion and interest” amounts were disclosed for
Q3 FY2025, Q2 FY2025, Q1 FY2025, and Q3 FY2024; other quarters not
disclosed (N/A).</li>
<li>Cash from operating activities: the MD&amp;A provides qualitative
commentary but no period-specific CFO amounts; therefore shown as N/A.
Capital expenditures (PP&amp;E additions) of 1,350,411 are for the nine
months ended June 30, 2025; quarterly capex split not disclosed.</li>
<li>Free Cash Flow (FCF) is presented as N/A where CFO is not disclosed.
If CFO were provided, FCF would be CFO − capex.</li>
<li>9M FY2025 totals are simple sums of the three quarterly figures
where disclosed: Revenue (437,806 + 726,968 + 460,139) = 1,624,913; Net
loss (−2,002,994 − 1,547,308 − 1,955,353) = −5,505,655; Gross profit
(51,316 + 269,997 + 85,672) = 406,985; Grant income (159,575 + 298,244 +
0) = 457,819; Share-based comp (231,403 + 140,642 + 137,796) = 509,841;
Finance costs (82,975 + 84,983 + 95,145) = 263,103.</li>
<li>Depreciation and amortization 9M sums are not shown in the table as
precise consolidated totals require segment detail for Q1–Q2
discontinued items; per-quarter values are listed.</li>
</ul>
<h2 id="capitalization-cash-debt-and-enterprise-value">Capitalization,
Cash, Debt, and Enterprise Value</h2>
<p>Assumptions and sources:</p>
<ul>
<li>Share counts as of August 28, 2025 from “Outstanding Share Data”:
Common Shares 128,962,139; Options 7,935,950; Unit Warrants 11,779,725;
RSUs 2,369,438; SARs 580,000; Total securities 151,627,252.</li>
<li>Stock price: $0.19 CAD (provided by user).</li>
<li>Cash: $964,858 at June 30, 2025 (Cash Flow section). Note: a
separate reference in Risk Management cites $1,577,074; we use the
explicit cash balance disclosed in the cash flow discussion.</li>
<li>Debt: Loans payable $3,674,474 and lease liabilities $1,497,904 at
June 30, 2025.</li>
<li>Fully diluted methodology:
<ul>
<li>TSM FD (in-the-money) includes only instruments with zero or
below‑market strike. All listed options/warrants have strikes
≥$0.28–$0.45, thus out-of-the-money at $0.19. RSUs assumed zero exercise
price and included. SARs terms not specified; excluded from TSM FD.</li>
<li>All-in FD (if-converted) includes all options, warrants, RSUs, and
SARs; equals the “Total Securities” figure in the MD&amp;A.</li>
</ul></li>
<li>Pro forma: Post‑Q3 2025 $8m BMI project‑level equity (Thorold SPV)
does not change parent share count; staged SPV funding (non‑recourse)
not included in EV as of June 30, 2025 due to timing/structure and lack
of consolidated cash detail.</li>
</ul>
<table>
<colgroup>
<col style="width: 44%" />
<col style="width: 55%" />
</colgroup>
<thead>
<tr>
<th>Item</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Price</td>
<td>$0.19 CAD</td>
</tr>
<tr>
<td>Basic Shares</td>
<td>128,962,139</td>
</tr>
<tr>
<td>Fully Diluted Shares (TSM FD, in-the-money only)</td>
<td>131,331,577 = Basic + RSUs (2,369,438)</td>
</tr>
<tr>
<td>Fully Diluted Shares (All-in, if-converted)</td>
<td>151,627,252 = Basic + all options, warrants, RSUs, SARs</td>
</tr>
<tr>
<td>Implied Market Cap (Basic)</td>
<td>$24.503m = 128,962,139 × $0.19</td>
</tr>
<tr>
<td>Implied Market Cap (TSM FD)</td>
<td>$24.953m = 131,331,577 × $0.19</td>
</tr>
<tr>
<td>Implied Market Cap (All-in FD)</td>
<td>$28.809m = 151,627,252 × $0.19</td>
</tr>
<tr>
<td>Cash (6/30/2025)</td>
<td>$0.965m</td>
</tr>
<tr>
<td>Loans Payable (Debt)</td>
<td>$3.674m</td>
</tr>
<tr>
<td>Lease Liabilities</td>
<td>$1.498m</td>
</tr>
<tr>
<td>Net Debt (excl. leases)</td>
<td>$2.710m = $3.674m − $0.965m</td>
</tr>
<tr>
<td>Net Debt (incl. leases)</td>
<td>$4.208m = ($3.674m + $1.498m) − $0.965m</td>
</tr>
<tr>
<td>EV (Basic, excl. leases)</td>
<td>$27.213m = $24.503m + $2.710m</td>
</tr>
<tr>
<td>EV (TSM FD, excl. leases)</td>
<td>$27.663m = $24.953m + $2.710m</td>
</tr>
<tr>
<td>EV (All-in FD, excl. leases)</td>
<td>$31.519m = $28.809m + $2.710m</td>
</tr>
<tr>
<td>EV (Basic, incl. leases)</td>
<td>$28.711m = $24.503m + $4.208m</td>
</tr>
<tr>
<td>EV (TSM FD, incl. leases)</td>
<td>$29.161m = $24.953m + $4.208m</td>
</tr>
<tr>
<td>EV (All-in FD, incl. leases)</td>
<td>$33.017m = $28.809m + $4.208m</td>
</tr>
<tr>
<td>Pro forma adjustments</td>
<td>None to parent-level shares/EV for BMI’s July 10, 2025 $8m project
equity; staged SPV cash not reflected at 6/30/2025</td>
</tr>
</tbody>
</table>
<h2 id="valuation">Valuation</h2>
<p>Assumptions and sources:</p>
<ul>
<li>MD&amp;A for the quarter ended June 30, 2025 (discussion dated Aug
28, 2025). Share data: “Outstanding Share Data.” Cash, loans, leases as
at June 30, 2025 from Cash Flow/Liquidity sections. Quarterly gross
profit, expense components from “Discussion of Operations” and “Eight
Quarter Summary” footnotes. Discontinued operations Q3 FY2025/Q3 FY2024
from “Discussion of Discontinued Operations.”</li>
<li>LTM period: Q4 FY2024 (Sep 30, 2024) + Q1 FY2025 (Dec 31, 2024) + Q2
FY2025 (Mar 31, 2025) + Q3 FY2025 (Jun 30, 2025).</li>
<li>EBIT definition per user: Gross Profit − Operating Expenses,
excluding finance costs and taxes. Based on quarterly disclosures:
<ul>
<li>Q4 FY2024 EBIT ≈ −$2.561m (Gross Profit $0.531m − Operating Expenses
$3.092m including impairments; no finance costs disclosed).</li>
<li>Q1 FY2025 EBIT ≈ −$1.681m (Gross Profit $0.086m − OpEx excl.
interest $1.766m).</li>
<li>Q2 FY2025 EBIT ≈ −$1.744m (Gross Profit $0.270m − OpEx excl.
interest $2.014m).</li>
<li>Q3 FY2025 EBIT ≈ −$2.085m (Consolidated: Continuing EBIT −$2.078m +
Discontinued EBIT −$0.008m).</li>
<li>LTM EBIT ≈ −$8.072m = sum of above.</li>
</ul></li>
<li>EBIT calculations exclude accretion/interest; impairments included
as operating costs for Q4 FY2024 as disclosed. Q2–Q1 FY2025 operating
expense components taken from footnote detail; where line items (e.g.,
regulatory fees) were not listed, assumed immaterial for the
quarter.</li>
<li>EBITDA = EBIT + Depreciation + Amortization. LTM D&amp;A sum ≈
$1.293m (Q4’24 $0.277m, Q1’25 $0.300m, Q2’25 $0.313m, Q3’25 $0.403m).
LTM EBITDA ≈ −$6.779m.</li>
<li>Adjusted EBITDA: not disclosed; per instruction, use EBITDA in its
place.</li>
<li>Unlevered Free Cash Flow (UFCF) = FCF + finance costs. CFO/FCF not
provided numerically; investing activity includes ~$1.35m PP&amp;E
additions for 9M FY2025 and $0.271m asset sale proceeds, but without
quantified CFO, FCF/UFCF cannot be reliably derived.</li>
<li>EV used: present multiples on EV excluding leases; results including
leases are similar and can be derived if needed.</li>
</ul>
<table>
<thead>
<tr>
<th>Metric</th>
<th>Basic</th>
<th>Fully Diluted (TSM FD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EV/EBIT</td>
<td>nm (negative)</td>
<td>nm (negative)</td>
</tr>
<tr>
<td>EV/adjusted EBITDA (EBITDA)</td>
<td>nm (negative)</td>
<td>nm (negative)</td>
</tr>
<tr>
<td>EV/unlevered FCF</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
</body>
</html>
